VA
ACAD icon

Vident Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Vident Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,179
Closed -$230K – 1409
2024
Q2 		$230K Buy
+14,179
New +$229K 0.01% 1225
2024
Q1 		– Sell
-7,279
Closed -$228K – 1324
2023
Q4 		$228K Buy
+7,279
New +$174K 0.01% 1152

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Vident Advisory's ACAD Position: Q3 2024 in Review

Vident Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 14,179 shares — an estimated $230K sold.

Vident Advisory first reported a position in ACAD in Q4 2023 and held it in 2 quarters. The position peaked at $230K in Q2 2024. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Vident Advisory reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 14,179 Acadia Pharmaceuticals shares in Q3 2024, an estimated $230K.
  • Vident Advisory first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Vident Advisory's Acadia Pharmaceuticals position peaked at $230K in Q2 2024.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.